PCM
APLS

Pentwater Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Pentwater Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$211M Buy
+5,250,000
New +$113M 1.1% 21

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Pentwater Capital Management's APLS Position: Q1 2026 in Review

Pentwater Capital Management opened a new position in Apellis Pharmaceuticals (APLS) in Q1 2026: 5,250,000 shares worth $211M. The stake represents 1.1% of the portfolio and ranks #21 among its holdings.

323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Pentwater Capital Management held 5,250,000 shares of Apellis Pharmaceuticals worth $211M as of Q1 2026.
  • Apellis Pharmaceuticals was a new Pentwater Capital Management position in Q1 2026.
  • Apellis Pharmaceuticals made up 1.1% of Pentwater Capital Management's portfolio in Q1 2026, its #21 holding.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Pentwater Capital Management's 13F filing for Q1 2026, filed 15 May 2026.